# A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

> **NCT01021527** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **OTHER:** Comparator: Treatment A
- **DRUG:** Comparator: Treatment B
- **DRUG:** Comparator: Treatment C
- **PROCEDURE:** Comparator: graded glucose infusion

## Key facts

- **NCT ID:** NCT01021527
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021527, "A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01021527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*